In the early treatment of type 2 diabetes mellitus (T2DM), the addition of a basal insulin, such as insulin glargine, to existing oral therapy can help patients attain recommended glycaemic control targets, including haemoglobin A1c (HbA1c) <7%>
Copyright (C) 2008 Blackwell Publishing Ltd.
